Novartis to Acquire Avidity Biosciences for $12 Billion

In-Depth Analysis

Novartis’ acquisition of Avidity Biosciences signifies a strategic investment in RNA-based therapies, a relatively new class of medications that alter gene expression to treat or prevent diseases. Avidity specializes in Antibody Oligonucleotide Conjugates (AOCs™), which enable targeted delivery of RNA therapeutics to muscle tissue. This deal aligns with Novartis’ broader strategy of expanding its research and development division, including a $23 billion investment to build out its U.S.-based infrastructure. The acquisition is expected to provide Novartis with potential first-in-class, late-stage disease-modifying therapies in myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD).

Read source article

FAQ

What are Antibody Oligonucleotide Conjugates (AOCs™)?

AOCs are a class of RNA therapeutics developed by Avidity Biosciences that combine monoclonal antibodies with oligonucleotides for targeted delivery to muscle cells.

When is the acquisition expected to close?

The deal is expected to close in the first half of 2026, subject to customary closing conditions and the completion of Avidity’s spin-off of its early-stage cardiology programs.

Takeaways

Novartis is acquiring Avidity Biosciences to enhance its neuroscience pipeline and RNA therapeutics capabilities.
The acquisition will provide Novartis access to Avidity’s AOC platform, enabling targeted RNA delivery to muscle tissue.
The deal is expected to close in the first half of 2026 and is projected to increase Novartis’ sales growth rate.

Discussion

Do you think this acquisition will lead to significant advancements in the treatment of neuromuscular diseases? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!

Sources

Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis goes big for neuroscience with $12B deal for late-stage dystrophy biotech Avidity

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.